- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04224974
Essai d'engagement axé sur les émotions et les symptômes pour les personnes atteintes de leucémie aiguë (EASE)
Engagement centré sur les émotions et les symptômes (EASE) : un essai contrôlé randomisé multisite d'une intervention pour les personnes atteintes de leucémie aiguë
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Harriet Richardson
- Numéro de téléphone: 613-533-6430
- E-mail: hrichardson@ctg.queensu.ca
Sauvegarde des contacts de l'étude
- Nom: Lois Shepherd
- Numéro de téléphone: 613-533-6430
- E-mail: lshepherd@ctg.queensu.ca
Lieux d'étude
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Recrutement
- Regional Health Authority B, Zone 2
-
Contact:
- Alfonso Rivera Duarte
- Numéro de téléphone: 506 648-7109
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Recrutement
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contact:
- Alejandro Garcia-Horton
-
Kingston, Ontario, Canada, K7L 2V7
- Recrutement
- Kingston Health Sciences Centre
-
Contact:
- Annette Hay
- Numéro de téléphone: 77094 613 533-6430
-
Ottawa, Ontario, Canada, K1H 8L6
- Recrutement
- Ottawa Hospital Research Institute
-
Contact:
- Pierre Villeneuve
- Numéro de téléphone: 613
-
Toronto, Ontario, Canada, M5G 2M9
- Recrutement
- University Health Network
-
Contact:
- Gary Rodin
- Numéro de téléphone: 416 946-4504
-
Toronto, Ontario, Canada, M4N 3M5
- Recrutement
- Odette Cancer Centre
-
Contact:
- Lee Mozessohn
- Numéro de téléphone: 5847 416 480-5000
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Autre : Soins habituels
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
Expérimental: Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
Délai: 4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Évaluer l'effet de l'intervention EASE par rapport aux soins habituels pour réduire les symptômes de stress traumatique à l'aide du SASRQ
Délai: 8 semaines, 12 semaines et 26 semaines
|
8 semaines, 12 semaines et 26 semaines
|
|
|
Évaluer l'effet de l'intervention EASE sur les soins habituels pour réduire la gravité des symptômes physiques à l'aide du MSAS
Délai: 8 semaines, 12 semaines et 26 semaines
|
8 semaines, 12 semaines et 26 semaines
|
|
|
Évaluer l'effet de l'intervention EASE par rapport aux soins habituels sur le nombre de participants répondant aux critères compatibles avec un diagnostic de TSA et au seuil de TSA basé sur les critères du DSM-5 à l'aide du SASRQ
Délai: 4, 8, 12 et 26 semaines
|
4, 8, 12 et 26 semaines
|
|
|
Évaluer l'effet de l'intervention EASE par rapport aux soins habituels sur le nombre de symptômes physiques du cancer et la détresse liée aux symptômes associée, telle que mesurée par le (MSAS)
Délai: 4, 8, 12 & 26 semaines
|
4, 8, 12 & 26 semaines
|
|
|
Évaluer l'effet de l'intervention EASE par rapport aux soins habituels sur la satisfaction des patients à l'égard des soins à l'aide du FAMCAR-P16 à 16 items
Délai: 4, 8, 12 et 26 semaines
|
4, 8, 12 et 26 semaines
|
|
|
10) L'EQ-5D-5L sera utilisé pour mesurer l'état de santé générique afin qu'il puisse être utilisé pour calculer les années de vie ajustées sur la qualité (QALY) dans une évaluation économique qui compare les avantages et les coûts de l'intervention EASE
Délai: 4, 8, 12, 26 et 52 semaines
|
4, 8, 12, 26 et 52 semaines
|
|
|
Pour comparer la survie sans progression entre les bras de traitement
Délai: 1 an
|
1 an
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
Délai: 4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
Délai: 4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
Délai: 4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
Délai: 4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
Délai: Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Gary Rodin, Princess Margaret Hospital, Canada
- Chaise d'étude: Camilla Zimmerman, Princess Margaret Hospital, Canada
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- SC26
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .